A new report by the RAND Corporation estimates the potential future cost savings gained from the use of biosimilars in the United States at $54 billion over 10 years, and examines future policy issues surrounding this important market.
In the 7 years since the enactment of the Biologics Price Competition and Innovation Act (BCPIA), which authorized the FDA to create a new regulatory approval pathway for biosimilars, the agency has approved 7 biosimilars, 3 of which have been marketed. The BCPIA’s biosimilar approval pathway was designed to promote competition among drug manufacturers in order to lower prices and potentially increase access to medications.
Although the US biosimilars market is still in its infancy, there are over 60 biosimilar molecules in development for more than 20 reference biologics. A new report by the RAND Corporation, “Biosimilar Cost Savings in the United States: Initial Experience and Future Potential,” estimates the potential future cost savings gained from the use of biosimilars in the United States at $54 billion over 10 years, and examines future policy issues surrounding this important market. The research described in the RAND report was sponsored by Sandoz.
The report concludes that:
Forecasting the future of the US biosimilars market, the RAND report suggests that evolving payment arrangements, regulatory policies and guidance, patient and prescriber acceptance of biosimilars, and other factors will influence the magnitude of potential savings. Other drivers of spending on biosimilar drugs work with and through competition to determine biosimilars’ market share, prices, and impact on spending, the report explains: “We identified competition as the most important factor in determining impact on spending.”
The report outlines the most important features of the still-evolving biosimilars market:
The RAND report notes that the potential for cost savings will vary across biologic classes based on sales, degree of competition, and timing of biosimilar entry. Anti—tumor necrosis factor (TNF) products, monoclonal antibody antineoplastics, and immunostimulants excluding interferons alone account for 87% of estimated savings from biosimilars. (The anti–TNF agent category includes some of the largest biologic products by sales and biosimilars that are already marketed or close to market entry.)
The Future of the US Biosimilars Market
Several key challenges and sources of uncertainty concerning the US biosimilar market remain, including questions about whether the market is sustainable or will lead to the intended cost savings. In addition to the issue of interchangeability, price competition will be affected by non-price competition from reference biologic manufacturers because biologic manufacturers in some markets are developing next-generation biologics that offer improvements over older reference biologics facing potential biosimilar competition. These next-generation biologics will compete with biosimilars and older reference biologics for market share. In addition, biosimilar naming conventions using a distinguishing 4-letter suffix may affect perceptions and acceptance of biosimilars—prescribers and patients could perceive lower efficacy or different safety for biosimilars and avoid their use.
Finally, the RAND report presents US policymakers with 2 choices going forward: they can allow the market to continue to develop under current policies—for example, allowing increasing FDA and industry experience with approval requirements, building on an understanding of legal issues set through early Court decisions, and allowing evolving pricing and market-share trends to eventually provide clarity on the stability of the US biosimilar market. Alternatively, they can intervene and help steer the US biosimilars market more quickly to a sustainable, competitive state, for example, reworking Medicare’s drug payment policies to more actively incentivize biosimilar uptake by lowering or eliminating cost sharing for biosimilars.
Perceptions of Biosimilar Switching Among Veterans With IBD
December 2nd 2024Veterans with inflammatory bowel disease (IBD) prioritize shared decision-making, transparency, and individualized care in biosimilar switching, favoring delayed switching for severe cases and greater patient control.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
The Rebate War: How Originator Companies Are Fighting Back Against Biosimilars
November 25th 2024Few biologics in the US have multiple biosimilar competitors, but originator biologics respond quickly to competition by increasing rebates and lowering net prices, despite short approval-to-launch timelines for biosimilars.
Boosting Health Care Sustainability: The Role of Biosimilars in Latin America
November 21st 2024Biosimilars could improve access to biologic treatments and health care sustainability in Latin America, but their adoption is hindered by misconceptions, regulatory gaps, and weak pharmacovigilance, requiring targeted education and stronger regulations.